{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:20:00Z","timestamp":1793064000724,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Amyloid-\u03b2 PET and CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      yield discordant results in 10\u201320% of memory clinic patients, possibly providing unique information. Although the predictive power of demographic, clinical, genetic, and imaging features for amyloid positivity has previously been investigated, it is unknown whether these features differentially predict amyloid-\u03b2 status based on PET or CSF or whether this differs by disease stage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 768 patients (subjective cognitive decline (SCD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009194), mild cognitive impairment (MCI,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009127), dementia (AD and non-AD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009447) with amyloid-\u03b2 PET and CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      measurement within 1\u00a0year. Ninety-seven (13%) patients had discordant PET\/CSF amyloid-\u03b2 status. We performed parallel random forest models predicting separately PET and CSF status using 17 patient features (demographics, APOE4 positivity, CSF (p)tau, cognitive performance, and MRI visual ratings) in the total patient group and stratified by syndrome diagnosis. Thereafter, we selected features with the highest variable importance measure (VIM) as input for logistic regression models, where amyloid status on either PET or CSF was predicted by (i) the selected patient feature and (ii) the patient feature adjusted for the status of the other amyloid modality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      APOE4, CSF tau, and p-tau had the highest VIM for PET and CSF in all groups. In the amyloid-adjusted logistic regression models, p-tau was a significant predictor for PET-amyloid in SCD (OR\u2009=\u20091.02 [1.01\u20131.04],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009=\u20090.03), MCI (OR\u2009=\u20091.05 [1.02\u20131.07],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009&lt;\u20090.01), and dementia (OR\u2009=\u20091.04 [1.03\u20131.05],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009&lt;\u20090.001), but not for CSF-amyloid. APOE4 (OR\u2009=\u20093.07 [1.33\u20137.07],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>unc<\/jats:sub>\n                      \u2009&lt;\u20090.01) was associated with CSF-amyloid in SCD, while it was only predictive for PET-amyloid in MCI (OR\u2009=\u20099.44 [2.93, 30.39],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009&lt;\u20090.01). Worse MMSE scores (OR\u2009=\u20091.21 [1.03\u20131.41],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>unc<\/jats:sub>\n                      \u2009=\u20090.02) were associated to CSF-amyloid status in SCD, whereas worse memory (OR\u2009=\u20091.17 [1.05\u20131.31],\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009=\u20090.02) only predicted PET positivity in dementia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Amyloid status based on either PET or CSF was predicted by different patient features, and this varied by disease stage, suggesting that PET-CSF discordance yields unique information. The stronger associations of both APOE4 carriership and worse memory z-scores with CSF-amyloid in SCD suggest that CSF-amyloid is more sensitive early in the disease course. The higher predictive value of CSF p-tau for a positive PET scan suggests that PET is more specific to AD pathology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-019-0561-5","type":"journal-article","created":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:27Z","timestamp":1575676827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["PET and CSF amyloid-\u03b2 status are differently predicted by patient features: information from discordant cases"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-4986","authenticated-orcid":false,"given":"Juhan","family":"Reimand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Zwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N. M.","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,7]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 2015;313:1924\u201338 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4486209&tool=pmcentrez&rendertype=abstract.","journal-title":"Jama"},{"key":"561_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement"},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131:1630\u201345 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awn016.","journal-title":"Brain"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"561_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"561_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378 Available from: https:\/\/doi.org\/10.1016\/S1474-4422(12)70142-4.","journal-title":"Lancet Neurol"},{"key":"561_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652\u20136.","journal-title":"Neurology."},{"key":"561_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:280\u201392 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimer\u2019s Dement"},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimer\u2019s Dement"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:263\u20139 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimer\u2019s Dement"},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/brain\/awu387","volume":"138","author":"AM Fagan","year":"2015","unstructured":"Fagan AM. What does it mean to be \u201camyloid-positive\u201d? Brain. 2015;138:514\u20136 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awu387.","journal-title":"Brain"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med. 2009;1:371\u201380.","journal-title":"EMBO Mol Med"},{"key":"561_CR14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","volume":"86","author":"MD Zwan","year":"2016","unstructured":"Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleo A, Herukka SK, et al. Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study. Neurol Int. 2016;86:50\u20138 Available from: http:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-84952360236&partnerID=40&md5=63e500c4102f7bec04c2bb7ee968cb0b%5Cnhttp:\/\/www.neurology.org\/cgi\/doi\/10.1212\/WNL.0000000000002081%5Cnhttp:\/\/ovidsp.tx.ovid.com\/sp-3.18.0b\/ovidweb.cgi?WebLinkFrameset=1&S=IKPBF.","journal-title":"Neurol Int"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","volume":"36","author":"K Blennow","year":"2015","unstructured":"Blennow K, Mattsson N, Sch\u00f6ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer\u2019s disease. Trends Pharmacol Sci. 2015;36:297\u2013309.","journal-title":"Trends Pharmacol Sci"},{"key":"561_CR16","doi-asserted-by":"publisher","unstructured":"Arno de Wilde, Juhan Reimand, Charlotte E. Teunissen, Marissa Zwan, Albert D. Windhorst, Ronald Boellaard, Wiesje M. van der Flier, Philip Scheltens, Bart N.M. van Berckel, Femke Bouwman RO. Discordant amyloid-\u03b2 PET and CSF biomarkers and its clinical consequences (in press). Alzheimers Res Ther. 2019;11(1):78. https:\/\/doi.org\/10.1186\/s13195-019-0532-x","DOI":"10.1186\/s13195-019-0532-x"},{"key":"561_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid- and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138:772\u201383 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awu367.","journal-title":"Brain"},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/WNL.0b013e31826e2696","volume":"79","author":"MM Mielke","year":"2012","unstructured":"Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79:1570\u20137.","journal-title":"Neurology."},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.dadm.2016.07.002","volume":"4","author":"Philip S. Insel","year":"2016","unstructured":"Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, et al. Assessing risk for preclinical \u03b2-amyloid pathology with APOE, cognitive, and demographic information. Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit 2016;4:76\u201384. Available from: https:\/\/doi.org\/10.1016\/j.dadm.2016.07.002","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"561_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13195-018-0428-1","volume":"10","author":"M ten Kate","year":"2018","unstructured":"ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, et al. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers Res Ther. 2018;10:100 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30261928%0Ahttps:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0428-1.","journal-title":"Alzheimers Res Ther"},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JAD-150247","volume":"48","author":"QX Li","year":"2015","unstructured":"Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, et al. Alzheimer\u2019s disease normative cerebrospinal fluid biomarkers validated in PET amyloid-\u03b2 characterized subjects from the Australian imaging, biomarkers and lifestyle (AIBL) study. J Alzheimers Dis. 2015;48:175\u201387.","journal-title":"J Alzheimers Dis"},{"key":"561_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain. 2016;139:1226\u201336 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/aww015.","journal-title":"Brain"},{"key":"561_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM Van Der Flier","year":"2018","unstructured":"Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091\u2013111.","journal-title":"J Alzheimers Dis"},{"key":"561_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM Van Der Flier","year":"2014","unstructured":"Van Der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimers Dis. 2014;41:313\u201327.","journal-title":"J Alzheimers Dis"},{"key":"561_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology."},{"key":"561_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Roman","year":"1993","unstructured":"Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN internal workshop. Neurology. 1993;43:250\u201360.","journal-title":"Neurology."},{"key":"561_CR27","doi-asserted-by":"crossref","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863\u201372.","DOI":"10.1212\/01.wnl.0000187889.17253.b1"},{"key":"561_CR28","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden J, Gustafson L, Passant U, Stuss D, Black SE, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurol Int. 1998;51:1546\u201354 Available from: http:\/\/www.neurology.org\/cgi\/content\/full\/51\/6\/1546.","journal-title":"Neurol Int"},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"02","author":"M Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini M, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurologyogy. 2011;02:1006\u201314.","journal-title":"Neurologyogy."},{"key":"561_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1\u20139.","journal-title":"Neurology."},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ana.10570","volume":"54","author":"BF Boeve","year":"2003","unstructured":"Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54:15\u20139.","journal-title":"Ann Neurol"},{"key":"561_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurol Int. 2013;80:496\u2013503 Available from: www.neurology.org.","journal-title":"Neurol Int"},{"issue":"9","key":"561_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S. Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low P a, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18725592%0Ahttp:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC2676993","journal-title":"Neurology"},{"key":"561_CR34","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/WNL.0000000000004802","volume":"90","author":"C Groot","year":"2018","unstructured":"Groot C, Van Loenhoud AC, Barkhof F, Van Berckel BNM, Koene T, Teunissen CC, et al. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2018;90:e149\u201356.","journal-title":"Neurology."},{"key":"561_CR35","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1212\/WNL.0000000000000432","volume":"82","author":"R Ossenkoppele","year":"2014","unstructured":"Ossenkoppele R, Van Der Flier WM, Verfaillie SCJ, Vrenken H, Versteeg A, Van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 2014;82:1768\u201375.","journal-title":"Neurology."},{"key":"561_CR36","first-page":"111","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit. 2017;8:111\u201326.","journal-title":"Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit"},{"issue":"1","key":"561_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jalz.2017.06.2264","volume":"14","author":"Suzanne E. Schindler","year":"2018","unstructured":"Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, et al. Upward drift in cerebrospinal fluid amyloid \u03b2 42 assay values for more than 10 years. Alzheimer\u2019s Dement; 2018;14:62\u201370. Available from: https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2264","journal-title":"Alzheimer's & Dementia"},{"key":"561_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, Van Berckel BNM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2018;64:576\u201385.","journal-title":"Clin Chem"},{"key":"561_CR39","doi-asserted-by":"crossref","unstructured":"de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EAJ, et al. Alzheimer\u2019s biomarkers in daily practice project: rationale and design. Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit. 2017;143\u201351. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352872917300039","DOI":"10.1016\/j.dadm.2017.01.003"},{"key":"561_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2019.00007","volume":"11","author":"SCJ Verfaillie","year":"2019","unstructured":"Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, et al. Amyloid-\u03b2 load is related to worries, but not to severity of cognitive complaints in individuals with subjective cognitive decline: the SCIENCe project. Front Aging Neurosci. 2019;11:1\u20139.","journal-title":"Front Aging Neurosci"},{"key":"561_CR41","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"BNM van Berckel","year":"2013","unstructured":"van Berckel BNM, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570\u20136 Available from: http:\/\/jnm.snmjournals.org\/cgi\/doi\/10.2967\/jnumed.112.113654.","journal-title":"J Nucl Med"},{"key":"561_CR42","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00259-012-2102-3","volume":"39","author":"R Ossenkoppele","year":"2012","unstructured":"Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990\u20131000.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"561_CR43","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, Van Der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer\u2019s dement. 2013;9:414\u201321 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2012.07.003.","journal-title":"Alzheimer\u2019s dement"},{"key":"561_CR44","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort. JAMA Neurol. 2018;75:1062\u201370 Available from: http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.1346.","journal-title":"JAMA Neurol"},{"key":"561_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FRJ, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9:2 Available from: http:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-016-0228-4.","journal-title":"Alzheimers Res Ther"},{"key":"561_CR46","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"ELGE Koedam","year":"2011","unstructured":"Koedam ELGE, Lehmann M, Van Der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol. 2011;21:2618\u201325.","journal-title":"Eur Radiol"},{"key":"561_CR47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"561_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HIZR. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging deficiency. AJR Am J Roentgenol. 1987;149:351\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"561_CR49","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4317324&tool=pmcentrez&rendertype=abstract.","journal-title":"Alzheimers Dement"},{"key":"561_CR50","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018. p. https:\/\/www.R-project.org\/."},{"key":"561_CR51","doi-asserted-by":"publisher","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3). https:\/\/doi.org\/10.18637\/jss.v045.i03.","DOI":"10.18637\/jss.v045.i03"},{"key":"561_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45:5\u201332.","journal-title":"Mach Learn"},{"key":"561_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-9-307","volume":"9","author":"C Strobl","year":"2008","unstructured":"Strobl C, Boulesteix AL, Kneib T, Augustin T, Zeileis A. Conditional variable importance for random forests. BMC Bioinformatics. 2008;9:1\u201311.","journal-title":"BMC Bioinformatics"},{"key":"561_CR54","volume-title":"Out-of-bag estimation","author":"OEL Breiman","year":"1996","unstructured":"Breiman OEL, Berkeley C. Out-of-bag estimation; 1996."},{"key":"561_CR55","volume-title":"An AUC-based permutation variable importance measure for random forests an AUC-based permutation variable importance measure for random forests","author":"S Janitza","year":"2012","unstructured":"Janitza S, Strobl C. An AUC-based permutation variable importance measure for random forests an AUC-based permutation variable importance measure for random forests; 2012."},{"key":"561_CR56","doi-asserted-by":"crossref","unstructured":"Strobl C, Boulesteix AL, Zeileis A, Hothorn T. Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics. 2007;8:25.","DOI":"10.1186\/1471-2105-8-25"},{"key":"561_CR57","unstructured":"Burnham K, Anderson D. Model selection and multimodel inference: a practical information-theoretic approach, second edition. Ecol Model 2002. ISBN: 978-0-387-22456-5."},{"key":"561_CR58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"B Hochberg","year":"1995","unstructured":"Hochberg B. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289\u2013300 Available from: http:\/\/www.jstor.org\/stable\/2346101.","journal-title":"J R Stat Soc"},{"key":"561_CR59","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M, H\u00fcll M, Hampel H, Kessler H, et al. Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho-Tau in patients with low- and high-CSF A\u03b240 load. J Neurochem. 2007;101:1053\u20139.","journal-title":"J Neurochem"},{"key":"561_CR60","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/archneurol.2009.279","volume":"66","author":"NJ Cairns","year":"2009","unstructured":"Cairns NJ, Ikonomovic MD, Benzinger T, Fagan AM, Shah A, Schmidt RE, et al. Absence of PIttsburgh compound B detection of cerebral amyloid Beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease. Arch Neurol. 2009;66:1557\u201362.","journal-title":"Arch Neurol"},{"key":"561_CR61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature20814","volume":"541","author":"W Qiang","year":"2017","unstructured":"Qiang W, Yau W-M, Lu J-X, Collinge J, Tycko R. Structural variation in amyloid-\u03b2 fibrils from Alzheimer\u2019s disease clinical subtypes. Nature. 2017;541:217\u201321 Available from: http:\/\/www.nature.com\/doifinder\/10.1038\/nature20814.","journal-title":"Nature"},{"issue":"10","key":"561_CR62","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","volume":"14","author":"Oskar Hansson","year":"2018","unstructured":"Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: a review. Alzheimer\u2019s Dement. 2018:1313\u201333 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2018.05.008.","journal-title":"Alzheimer's & Dementia"},{"issue":"6","key":"561_CR63","doi-asserted-by":"publisher","first-page":"e100784","DOI":"10.1371\/journal.pone.0100784","volume":"9","author":"Stephanie J. B. Vos","year":"2014","unstructured":"Vos SJB, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, et al. Variability of CSF alzheimer\u2019s disease biomarkers: implications for clinical practice. PLoS One. 2014;9:e100784.","journal-title":"PLoS ONE"},{"issue":"3","key":"561_CR64","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"Niklas Mattsson","year":"2014","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-b and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138(3):772\u201383.","journal-title":"Brain"},{"key":"561_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Agren H. tau protein in cerebrospinal fluid. A biochemical marker. Mol Chem Neuropathol. 1995;26:231\u201345.","journal-title":"Mol Chem Neuropathol"},{"key":"561_CR66","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/JAD-2011-101911","volume":"25","author":"TT Sepp\u00e4l\u00e4","year":"2011","unstructured":"Sepp\u00e4l\u00e4 TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;25:583\u201394.","journal-title":"J Alzheimers Dis"},{"key":"561_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-9-22","volume":"9","author":"KR Wildsmith","year":"2014","unstructured":"Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, et al. Identification of longitudinally dynamic biomarkers in Alzheimer\u2019s disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener. 2014;9:1\u201314.","journal-title":"Mol Neurodegener"},{"key":"561_CR68","doi-asserted-by":"publisher","first-page":"226ra30","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med. 2014;6:226ra30 Available from: http:\/\/www.tandfonline.com\/doi\/abs\/10.1081\/AL-120016110.","journal-title":"Sci Transl Med"},{"key":"561_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"561_CR70","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid- burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci. 2009;106:6820\u20135 Available from: http:\/\/www.pnas.org\/cgi\/doi\/10.1073\/pnas.0900345106.","journal-title":"Proc Natl Acad Sci"},{"key":"561_CR71","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","volume":"14","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, et al. Prevalence of the apolipoprotein E \u03b54 allele in amyloid \u03b2 positive subjects across the spectrum of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:913\u201324.","journal-title":"Alzheimers Dement"},{"key":"561_CR72","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"561_CR73","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack CR, Holtzman DM. Biomarker modeling of Alzheimer\u2019s disease. Neuron. 2013;80:1347\u201358 Available from: https:\/\/doi.org\/10.1016\/j.neuron.2013.12.003.","journal-title":"Neuron"},{"issue":"2","key":"561_CR74","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3233\/JAD-170327","volume":"60","author":"Ellis Niemantsverdriet","year":"2017","unstructured":"Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, et al. The cerebrospinal fluid A\u03b21-42\/A\u03b21-40 Ratio improves concordance with amyloid-PET for diagnosing Alzheimer\u2019s disease in a clinical setting. J Alzheimers Dis. 2017;60:561\u201376.","journal-title":"Journal of Alzheimer's Disease"},{"issue":"2","key":"561_CR75","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"Piotr Lewczuk","year":"2016","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid A\u03b242\/40 Corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:813\u201322.","journal-title":"Journal of Alzheimer's Disease"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0561-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T03:50:17Z","timestamp":1722138617000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0561-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0561-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/673467","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local medical ethics committee of VU University Medical Center has approved a general protocol for biobanking and using the clinical data for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}